Middle East And Africa Branded Generics Market
市场规模（十亿美元）
CAGR :
% 
USD
20.89 Billion
USD
34.25 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 20.89 Billion |
 Market Size (Forecast Year) |
USD 34.25 Billion |
 CAGR |
% |
| Major Markets Players |
|
中東和非洲品牌仿製藥市場細分，按藥物類別（抗高血壓藥、荷爾蒙藥物、抗代謝藥、降脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥及其他）、應用領域（心血管疾病、疼痛管理和抗發炎、腫瘤、糖尿病、神經系統疾病、胃腸道疾病、皮膚病及其他）、給藥途徑（口服、注射、外用及其他）、產品類型（加值品牌仿製藥、商品名仿製藥）、患者人群（成人、老年人、兒童）、最終用戶（醫院、診所、家庭護理、學術和研究機構及其他）、分銷渠道（零售藥店、醫院藥房、直接招標及其他）劃分——行業趨勢及至2032年的預測
中東和非洲品牌仿製藥市場規模
- 2024年中東和非洲品牌仿製藥市場價值為208.9億美元，預計到2032年將達到342.5億美元。
- 在2025年至2032年的預測期內，該市場預計將以6.4%的複合年增長率成長，主要驅動因素包括醫療保健支出增加、慢性病盛行率上升以及已開發市場和新興市場對價格合理、高品質藥物的需求。
- 這一增長也受到原研藥專利到期、政府支持經濟有效療法的政策、新興經濟體醫療保健覆蓋範圍擴大以及數位醫療和電子藥房管道日益普及的推動。此外，領先製藥公司在藥物製劑方面的持續創新、改進的患者依從性策略以及不斷擴大的品牌仿製藥產品組合，預計也將加速全球市場的擴張。
中東和非洲品牌仿製藥市場分析
- 中東和非洲品牌仿製藥市場正經歷強勁成長，這主要得益於消費者對兼具仿製藥價格優勢和品牌知名度的高品質、高性價比藥品的需求不斷增長。品牌仿製藥在提高患者用藥依從性、擴大基本藥物的可及性以及為新興市場和已開發市場的製藥公司創造收入機會方面發揮著至關重要的作用。該市場面臨的挑戰包括各國監管差異、價格壓力以及為維持品牌忠誠度而需要持續創新。
- 慢性病管理、腫瘤、心血管和傳染病治療領域是關鍵的成長驅動力。非傳染性疾病盛行率的上升、公眾健康意識的增強以及新興經濟體醫療服務覆蓋範圍的擴大，都推動了對品牌仿製藥的需求。此外，生物相似藥和專科仿製藥的日益普及也正在重塑市場格局，它們在保持療效和安全性的同時，為昂貴的原廠藥提供了替代方案。製藥公司正利用行銷策略、病患教育和策略合作夥伴關係來提高品牌仿製藥的普及率。
- 沙烏地阿拉伯佔據市場主導地位，而阿拉伯聯合大公國是成長最快的國家，這得益於該地區完善的仿製藥生產能力、有利的政府政策以及不斷增長的醫療保健支出。
- 抗高血壓藥物預計將佔據市場主導地位，市場份額為 30.52%，這主要得益於患者對方便用藥、成本效益和廣泛適用性等因素的偏好。
報告範圍及中東和非洲品牌仿製藥市場細分
|
屬性 |
中東和非洲品牌仿製藥市場關鍵洞察 |
|
涵蓋部分 |
|
|
覆蓋國家/地區 |
中東和非洲
|
|
主要市場參與者 |
|
|
市場機遇 |
|
|
加值資料資訊集 |
除了對市場狀況（如市場價值、成長率、細分、地理覆蓋範圍和主要參與者）的洞察之外，Data Bridge Market Research 精心編制的市場報告還包括進出口分析、產能概覽、生產消費分析、價格趨勢分析、氣候變遷情境、供應鏈分析、價值鏈分析、原材料/消耗標準概覽、供應商選擇、PESTLE 分析、五力分析和監管框架。 |
中東和非洲品牌仿製藥市場趨勢
“對價格合理、品質優良的藥品需求不斷增長，推動中東和非洲品牌仿製藥市場成長”
- 醫療保健成本不斷上漲、人口老化以及慢性病和生活方式相關疾病的日益普遍，推動了中東和非洲對價格合理且品質優良的藥品的需求，從而促進了品牌仿製藥的成長。品牌仿製藥在保持高療效和安全性的同時，為原廠藥提供了一種經濟有效的替代方案，使其在已開發市場和新興市場都至關重要。
- 各國政府和醫療支付方正積極透過政策、報銷框架和仿製藥替代計劃來推廣品牌仿製藥的使用，以控制醫療支出、擴大治療覆蓋範圍並提高患者依從性。這些措施正在促進多個治療領域（包括心血管疾病、糖尿病、腫瘤和中樞神經系統疾病）的市場接受度。
- 例如，2024年3月，美國FDA批准了多種針對糖尿病和高血壓等高需求治療領域的新型品牌仿製藥，顯示市場研發管線日益活躍，監管機構也大力支持提供更具成本效益的品牌藥替代品。這說明中東和非洲的品牌仿製藥市場正在持續擴張，以滿足患者和醫療保健系統的需求。
- 新興經濟體，尤其是沙烏地阿拉伯和拉丁美洲，由於醫療基礎設施的不斷完善、中產階級人口的壯大以及政府為提高治療可及性而採取的舉措，品牌仿製藥的普及速度正在加快。各公司正在擴大本地生產規模、增加研發投入並改善分銷網絡，以滿足這些地區日益增長的需求。
- 隨著中東和非洲的醫療保健系統繼續強調可負擔性、可近性和治療依從性，品牌仿製藥在確保可持續醫療保健服務方面的作用將變得越來越重要，同時推動製造、包裝和以患者為中心的藥物開發方面的創新。
中東和非洲品牌仿製藥市場動態
司機
“重磅藥物專利到期”
- 重磅藥物專利即將到期是推動中東和非洲品牌仿製藥市場擴張的最強勁的結構性因素之一。當高收入的創新藥失去專利保護期時，仿製藥和生物相似藥生產商便可推出競爭版本，從而削弱創新藥的市場份額，並將需求轉向價格更低的替代藥物。
- 這場「專利懸崖」引發了一系列下游效應：製造商爭相提交簡略新藥申請（ANDA）或生物類似藥申請，監管機構加快審查，支付方越來越傾向於仿製藥，患者可以獲得更便宜的品牌仿製藥。
- 過去十年間，大型治療藥物專利保護期的大量喪失，為仿製藥現有廠商和新進業者創造了反覆出現的機遇窗口，重塑了價格格局，促進了仿製藥生產的整合，並加速了其向新興市場的地域擴張。事實上，專利到期帶來的巨大收益往往為投資研發複雜的仿製藥和生物相似藥提供了經濟上的合理性。
- 重要的是，專利懸崖的時機和可預測性為仿製藥公司提供了戰略規劃窗口，使其能夠提前預估產品上市時間、投資研發管線、建立聯盟，並在專利獨佔權喪失前預先提交監管文件。
- 因此，品牌仿製藥領域成為一個週期性競爭的前沿陣地，與重磅藥物專利到期密切相關。
克制/挑戰
“專利訴訟與智慧財產權風險”
- 專利訴訟和智慧財產權風險對中東和非洲品牌仿製藥市場構成重大限制。專利糾紛的複雜性和持續時間可能延緩仿製藥的上市，阻礙市場競爭，並導致藥品價格居高不下。
- 這些法律糾紛通常涉及多層專利權主張，包括用途專利和次要專利，這可以延長品牌藥的獨佔期，使其超過其原始專利到期日。
- 此外，應對專利侵權訴訟的經濟負擔可能會阻礙仿製藥生產商，尤其是規模較小的公司進入市場。專利法的不斷演變以及原廠藥公司對專利組合的策略性運用，進一步加劇了市場動態的複雜性，並可能導致全球範圍內出現品牌藥與仿製藥並存的市場格局。
- 例如，2025年10月，《經濟時報》報道稱，總部位於海得拉巴的Natco Pharma公司贏得了與瑞士製藥公司羅氏就治療脊髓性肌肉萎縮症藥物Risdiplam的專利糾紛。
- 這些法律和財務障礙既影響製造商的獲利能力，也影響病患取得價格合理的藥品。總體而言，專利訴訟和智慧財產權風險仍然是影響中東和非洲品牌仿製藥市場競爭和成長的關鍵限制因素。
中東和非洲品牌仿製藥市場範圍
中東和非洲品牌仿製藥市場分為七個主要部分，這些部分是根據藥物類別、應用、給藥途徑、產品類型、患者人口統計特徵、最終用戶和分銷管道劃分的。
• 依藥物類別
根據藥物類別，中東和非洲品牌仿製藥市場可細分為抗高血壓藥、荷爾蒙藥物、抗代謝藥、降血脂藥、抗癲癇藥、烷化劑、抗憂鬱藥、抗精神病藥及其他藥物。預計到2025年，抗高血壓藥物將佔據市場主導地位，市場份額達30.52%，這主要得益於心血管疾病患病率的上升、高血壓管理意識的增強以及患者和醫療服務提供者對經濟實惠的仿製藥替代品的日益青睞。
預計在 2025 年至 2032 年的預測期內，抗高血壓藥物市場將以 8.0% 的複合年增長率增長，這主要得益於固定劑量複方療法的不斷創新、政府推廣平價藥物的舉措以及新興經濟體醫療保健覆蓋範圍的擴大，這些因素共同製藥的普及。
• 透過申請
根據應用領域，市場可細分為心血管疾病、疼痛管理和抗發炎、腫瘤、糖尿病、神經系統疾病、胃腸道疾病、皮膚病及其他領域。預計到2025年，心血管疾病領域將佔據市場主導地位，市場份額達36.62%，這主要得益於全球心臟相關疾病患病率的上升、老年人口的增長、人們對心血管疾病預防保健意識的提高以及經濟實惠的品牌仿製藥的普及。
預計心血管疾病領域將以 7.4% 的複合年增長率穩步增長，因為新興市場的醫療保健系統提高了基本藥物的可及性，固定劑量組合療法越來越受歡迎，並且持續的研究和開發提高了品牌仿製藥在心血管治療中的療效和安全性。
• 依管理途徑
根據給藥途徑，中東和非洲品牌仿製藥市場可分為口服、注射、外用和其他給藥途徑。預計到2025年，口服給藥途徑將佔據市場主導地位，市場份額達60.45%，這主要歸功於口服給藥的便利性、患者依從性高、口服製劑的廣泛可及性以及與其他給藥途徑相比的成本效益。
預計在預測期內，口服藥物市場將加速成長 6.6%，這得益於需要長期用藥的慢性疾病盛行率不斷上升、人們對自我給藥療法的偏好日益增強，以及具有更高生物利用度和更人性化設計的創新口服製劑的不斷推出。
• 依產品類型
根據產品類型，市場可分為高附加價值品牌仿製藥和商品名仿製藥。預計到2025年，高附加價值品牌仿製藥將佔據市場主導地位，市場份額達70.32%，這主要得益於其更高的療效、更佳的安全性、以患者為中心的配方以及與標準仿製藥相比更具差異化的治療優勢。
由於醫療保健提供者越來越傾向於選擇能夠提高患者依從性的製劑、對聯合療法的需求不斷增長、藥物輸送技術的持續創新以及對解決慢性病和復雜疾病治療中未滿足的醫療需求的關注，增值品牌仿製藥細分市場的重要性日益凸顯，並以 6.5% 的複合年增長率增長。
• 依患者人口統計特徵
根據患者人口統計數據，市場分為成人、老年和兒童三個部分。預計到2025年，成人市場將佔據主導地位，市場份額達68.75%，這主要是由於成人人群中慢性病和生活方式相關疾病（如心血管疾病、糖尿病和高血壓）的患病率較高，從而推動了對品牌仿製藥的持續需求。
預計成人市場將以 6.5% 的複合年增長率增長，這主要得益於醫療保健意識的提高、獲得價格合理的藥物的機會增加、新興經濟體中產階級人口的增長，以及成人患者對具有更好療效和依從性的增值品牌仿製藥的偏好。
• 由最終用戶
根據最終用戶劃分，市場可分為醫院、診所、家庭護理機構、學術及研究機構和其他機構。預計到2025年，醫院將佔據市場主導地位，市場份額達56.55%，這主要得益於醫院龐大的患者治療量、對品牌藥和高品質仿製藥在重症監護方面的偏好，以及醫院集中採購模式確保了基本藥物的穩定供應。
預計在 2025 年至 2032 年期間，醫院業將錄得最快的增長速度，達到 6.7%，這主要得益於醫院基礎設施的擴張、專科醫院和綜合醫院數量的增加、慢性病和急性病住院人數的上升，以及為了改善治療效果，住院治療中越來越多地採用增值仿製藥。
• 透過分銷管道
根據分銷管道，市場可細分為零售藥局、醫院藥房、直接招標和其他管道。預計到2025年，零售藥局通路將佔據市場主導地位，市佔率達57.45%，這主要得益於品牌仿製藥透過零售網點的廣泛供應、消費者對便捷購藥的需求，以及連鎖藥局和獨立藥局在城市和半城市地區的強大影響力。
預計在 2025 年至 2032 年期間，零售藥局行業將以 6.6% 的最快增速增長，這主要得益於自我用藥趨勢的增加、人們對經濟實惠的品牌仿製藥的認識不斷提高、藥店網絡的擴張以及政府通過零售渠道支持以可負擔的價格獲得基本藥物的舉措。
中東和非洲品牌仿製藥市場—區域分析
- 預計到 2025 年，沙烏地阿拉伯將以 28.55% 的最大收入份額主導中東和非洲品牌仿製藥市場，這主要得益於該地區對價格實惠且品質優良的藥品的強勁需求以及不斷增長的醫療保健支出。
- 政府加強對醫療保健基礎設施的支持力度、慢性病患病率不斷上升以及人們對治療依從性的認識不斷提高，這些因素共同推動了品牌仿製藥的普及。
- 印度、中國、日本和韓國等國家憑藉其完善的藥品生產能力、對仿製藥的監管支持以及對國內醫療保健生產不斷增長的投資，在該地區處於領先地位。
- 此外，沙烏地阿拉伯推出的有利於本地藥品生產、醫療保健和藥品出口的政策，進一步加速了該國的市場成長。
中東和非洲品牌仿製藥市場洞察
中東和非洲地區是中東和非洲品牌仿製藥市場的新興成長區域，這得益於醫療保健服務的普及、基礎設施的擴建以及政府為提高治療可及性而採取的各項舉措。沙烏地阿拉伯、阿聯酋和南非等國正在投資本地藥品生產、醫療保健現代化和數位醫療項目，這些舉措正在推動市場接受度。儘管與其它地區相比，中東和非洲地區仍處於發展階段，但人們對經濟實惠的治療方案的認識不斷提高、醫療保健覆蓋範圍的擴大以及監管改革預計將推動該地區品牌仿製藥的長期穩定增長。
沙烏地阿拉伯、中東和非洲品牌仿製藥市場洞察
沙烏地阿拉伯憑藉其強大的醫療基礎設施、先進的藥品生產能力以及政府鼓勵國內藥品生產的舉措，在中東和非洲品牌仿製藥市場佔據重要地位。該國對慢性病管理、腫瘤和心血管治療的重視，推動了對品牌仿製藥的需求成長。此外，製藥公司與研究機構之間的策略合作，也促進了高價值仿製藥和專科療法的創新。法國日益重視醫療保健的可近性、可負擔性和治療依從性，進一步鞏固了其在歐洲醫藥領域的重要地位。
埃及、中東和非洲品牌仿製藥市場洞察
在醫療保健覆蓋範圍擴大、對價格合理的療法需求不斷增長以及慢性病管理方案日益普及的推動下，埃及正崛起為中東和非洲品牌仿製藥行業中一個快速增長的市場。該國對醫療現代化、數位醫療措施和區域藥品生產的重視，加速了品牌仿製藥的使用。此外，當地製造商、研究機構和國際製藥公司之間的合作，也促進了高品質仿製藥的創新和商業化。西班牙對醫療基礎設施的投資以及患者健康意識宣傳活動，也為埃及市場的穩定成長做出了貢獻。
南非、中東和非洲品牌仿製藥市場洞察
預計在預測期內，南非將成為中東和非洲地區複合年增長率最高的國家，這主要得益於醫療保健支出不斷增長、製藥業快速工業化以及慢性病和生活方式相關疾病患病率的上升。印度、中國和日本等國家引領成長，這得益於其不斷擴大的國內產能、成本效益高的藥品生產以及有利的監管政策。該地區強大的藥品出口能力、不斷提高的醫療保健服務覆蓋率以及本地藥品生產的舉措，進一步加速了市場成長。人們對治療依從性的日益重視以及對高品質、價格合理的藥品的需求，持續鞏固該地區在中東和非洲市場的主導地位。
市場上的主要市場領導者包括：
- 梯瓦製藥工業股份有限公司（以色列）
- Viatris 公司（美國）
- 山德士集團（瑞士）
- 瑞迪博士實驗室有限公司（印度）
- 太陽製藥工業有限公司（印度）
- 奧羅賓多製藥（印度）
- 西普拉製藥（印度）
- 費森尤斯卡比（德國）
- 雅培（美國）
- Glenmark 製藥公司（印度）
- Hikma Pharmaceuticals PLC（英國）
- 魯賓製藥（印度）
- Emcure製藥（印度）
- 博士倫健康公司（加拿大）
- Mankind Pharma（印度）
- Jubilant Pharma（印度）
- Natco Pharma（印度）
- ARISTO製藥有限公司（印度）
- Biocon有限公司（印度）
- Torrent Pharmaceuticals Ltd.（印度）
- Endo公司（美國）
- Alembic製藥有限公司（印度）
- SAGENT製藥（美國）
- Panacea Biotec（印度）
中東和非洲品牌仿製藥市場最新動態
- 2025年10月，美國FDA批准了UZEDY（利培酮）緩釋注射混懸液的適應症擴展。除成人外，該藥現獲準用於治療13至17歲兒童及青少年的精神分裂症。這為患有這種慢性疾病的年輕患者提供了長效治療選擇。
- 2025年8月，梯瓦製藥（Teva）獲得美國FDA批准，推出了第一台Saxenda（利拉魯肽）注射仿製藥。這種仿製GLP-1受體激動劑核准用於成人和兒童患者的體重管理，為慢性體重管理提供了更方便的選擇。
- 2025年8月，Viatris公司首個用於治療缺鐵性貧血的藥物－蔗糖鐵注射劑仿製藥獲得美國FDA核准。這項進展為美國患者和醫療機構提供了更經濟實惠的治療選擇。此次獲準進一步豐富了Viatris公司的仿製注射劑產品組合，並提高了患者獲得此關鍵療法的途徑。
- 2025年4月，Viatris公司向日本厚生勞動省提交了補充新藥申請，尋求批准其藥物EFFEXOR（文拉法辛）用於治療廣泛性焦慮症。此舉旨在擴大該藥物在日本市場的治療用途。如果獲得批准，將為日本的廣泛性焦慮症患者提供新的治療選擇。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S FIVE FORCES ANALYSIS
4.2 BRAND OUTLOOK
4.2.1 PRODUCT VS BRAND OVERVIEW
4.2.1.1 PRODUCT OVERVIEW
4.2.1.2 BRAND OVERVIEW
4.3 CONSUMER BUYING BEHAVIOUR – MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
4.4 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 JOINT VENTURES
4.4.1.2 MERGERS AND ACQUISITIONS
4.4.1.3 LICENSING AND PARTNERSHIP
4.4.1.4 TECHNOLOGY COLLABORATIONS
4.4.1.5 STRATEGIC DIVESTMENTS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES AND MILESTONES
4.4.5 INNOVATION STRATEGIES AND METHODOLOGIES
4.4.6 RISK ASSESSMENT AND MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PATENT ANALYSIS – MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
4.5.1 PATENT QUALITY AND STRENGTH
4.5.2 PATENT FAMILIES
4.5.3 LICENSING AND COLLABORATIONS
4.5.4 REGIONAL PATENT LANDSCAPE
4.5.5 IP STRATEGY AND MANAGEMENT
4.6 PRICING ANALYSIS
4.7 VALUE CHAIN ANALYSIS
4.7.1 OVERVIEW
4.7.2 RAW MATERIAL SUPPLY
4.7.3 COMPONENT MANUFACTURING AND PROCESSING
4.7.4 EQUIPMENT AND TECHNOLOGY PROVIDERS
4.7.5 DISTRIBUTION AND LOGISTICS
4.7.6 END-USERS (BRANDS & INDUSTRY SECTORS)
4.7.7 CONCLUSION
5 REGULATION COVERAGE
5.1 REGULATION COVERAGE (NORTH AMERICA)
5.2 REGULATION COVERAGE (SOUTH AMERICA)
5.3 REGULATION COVERAGE (EUROPE)
5.4 REGULATION COVERAGE (MIDDLE EAST & AFRICA)
5.5 REGULATION COVERAGE (ASIA-PACIFIC)
5.6 SUPPLY CHAIN ANALYSIS OF MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
5.6.1 OVERVIEW
5.6.2 LOGISTIC COST SCENARIO
5.6.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
5.6.4 CONCLUSION
5.7 TECHNOLOGICAL ADVANCEMENTS– MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
5.7.1 ADVANCED FORMULATION TECHNOLOGIES
5.7.2 CONTINUOUS MANUFACTURING AND PROCESS OPTIMIZATION
5.7.3 ANTI-COUNTERFEITING AND SMART PACKAGING TECHNOLOGIES
5.7.4 MODIFIED DRUG DELIVERY SYSTEMS
5.7.5 DIGITAL TRANSFORMATION AND E-PRESCRIPTION INTEGRATION
5.7.6 ADVANCED ANALYTICAL AND QUALITY ASSURANCE TOOLS
5.7.7 PERSONALIZED GENERIC THERAPY DEVELOPMENT
5.7.8 SUSTAINABILITY AND ECO-FRIENDLY MANUFACTURING
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS
6.1.2 RISING PREVALENCE OF CHRONIC DISEASES
6.1.3 COST-EFFECTIVE ALTERNATIVE TO INNOVATOR DRUGS
6.1.4 SIMPLIFIED APPROVAL PATHWAYS FOR BRANDED GENERICS
6.2 RESTRAINS
6.2.1 PATENT LITIGATION AND INTELLECTUAL PROPERTY RISKS
6.2.2 COUNTERFEIT AND SUBSTANDARD DRUGS
6.3 OPPORTUNITIES
6.3.1 EXPANSION OF BRANDED GENERIC DRUG IN EMERGING MARKETS
6.3.2 PATENT CLIFF OF MAJOR DRUGS
6.3.3 EXPANSION INTO SPECIALTY AND COMPLEX GENERICS
6.4 CHALLENGES
6.4.1 INTENSE PRICE PRESSURE AMONG COMPETITORS
6.4.2 QUALITY PERCEPTION & PHYSICIAN/PATIENT TRUST IN BRANDED GENERIC DRUG
7 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET, BY DRUG CLASS
7.1 OVERVIEW
7.2 ANTI-HYPERTENSIVE
7.2.1 DIURETICS
7.2.2 CE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS)
7.2.3 ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS)
7.2.4 BETA BLOCKERS (BBS)
7.2.5 CALCIUM CHANNEL BLOCKERS (CCBS)
7.2.6 DIRECT VASODILATORS
7.2.7 ALPHA-1 BLOCKERS
7.2.8 CENTRAL ALPHA-2 AGONISTS
7.2.9 HORMONES
7.2.10 STEROID HORMONES
7.2.11 SEX HORMONES
7.2.12 ESTROGENS
7.2.13 PROGESTOGENS
7.2.14 ANDROGENS
7.2.15 THYROID HORMONES
7.2.16 OTHER HORMONES
7.3 ANTIMETABOLITES
7.3.1 PURINE ANALOGUES
7.3.2 PYRIMIDINE ANALOGUES
7.3.3 FOLATE ANTAGONISTS
7.4 LIPID LOWERING DRUGS
7.4.1 STATINS (HMG-COA REDUCTASE INHIBITORS)
7.4.2 COMBINATION PRODUCTS AND OTHER AGENTS
7.4.3 FIBRATES
7.4.4 BILE ACID SEQUESTRANTS
7.4.5 PCSK9 INHIBITORS
7.5 ANTI-EPILEPTICS
7.6 ALKYLATING AGENTS
7.6.1 NITROGEN MUSTARDS
7.6.2 NITROSOUREAS
7.6.3 ALKYL SULFONATES
7.6.4 TRIAZENES
7.6.5 ETHYLENIMINES
7.7 ANTI-DEPRESSANTS
7.7.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
7.7.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
7.7.3 TRICYCLIC ANTIDEPRESSANTS (TCAS)
7.7.4 ATYPICAL ANTIDEPRESSANTS
7.7.5 MONOAMINE OXIDASE INHIBITORS (MAOIS)
7.7.6 NMDA RECEPTOR ANTAGONISTS
7.8 ANTI-PSYCHOTICS
7.8.1 SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS
7.8.2 FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS
7.8.3 PHENOTHIAZINES
7.8.4 THIOXANTHENES
7.8.5 NEXT-GENERATION ANTIPSYCHOTICS
7.9 OTHERS
8 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 CARDIOVASCULAR DISEASES
8.3 PAIN MANAGEMENT AND ANTI-INFLAMMATORY
8.4 ONCOLOGY
8.5 DIABETES
8.6 NEUROLOGY
8.7 GASTROINTESTINAL DISEASES
8.8 DERMATOLOGY
8.9 OTHERS
9 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.3 INJECTABLEA
9.4 TOPICAL ADMINISTRATION
9.5 OTHERS
10 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE
10.1 OVERVIEW
10.2 VALUE-ADDED BRANDED GENERICS
10.3 TRADE NAMED GENERICS
11 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOMECARE
12.5 ACADEMIC & RESEARCH INSTITUTES
12.6 OTHERS
13 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 RETAIL PHARMACIES
13.3 HOSPITAL PHARMACIES
13.4 DIRECT TENDERS
13.5 OTHERS
14 MIDDLE EAST AND AFRICA SHIP REPAIR AND MAINTENANCE SERVICES MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SAUDI ARABIA
14.1.2 UNITED ARAB EMIRATES
14.1.3 EGYPT
14.1.4 SOUTH AFRICA
14.1.5 ISRAEL
14.1.6 KUWAIT
14.1.7 BAHRAIN
14.1.8 QATAR
14.1.9 OMAN
14.1.10 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: COMPANY LANDSCAPE
15.1 MANUFACTURER COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 SANDOZ GROUP AG
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR.REDDY’S LABORATORIES LTD.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 ALEMBIC PHARMACEUTICALS LIMITED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 AMNEAL PHARMACEUTICALS LLC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ARISTO PHARMACEUTICALS PRIVATE LIMITED
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ASPEN HOLDINGS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 AUROBINDO PHARMA USA (SUBSIDIARY OF AUROBINDO PHARMA LIMITED)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 BIOCON.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CIPLA
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 EMCURE PHARMACEUTICALS LIMITED
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 ENDO, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 FRESENIUS SE & CO. KGAA
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 GLENMARK PHARMACEUTICALS LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENTS
17.19 HIKMA PHARMACEUTICALS PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 INTAS PHARMACEUTICALS LTD.
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENTS
17.21 JUBILANT GENERICS LIMITED (SUBSIDIARY OF JUBILANT PHARMA COMPANY)
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 LUPIN
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
17.23 MANKIND PHARMA LIMITED
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
17.24 NATCO PHARMA LIMITED
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENTS
17.25 NEULAND LABORATORIES LTD.
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 ORCHIDPHARMA LTD.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENT
17.27 PANACEA BIOTEC
17.27.1 COMPANY SNAPSHOT
17.27.2 REVENUE ANALYSIS
17.27.3 PRODUCT PORTFOLIO
17.27.4 RECENT DEVELOPMENT
17.28 SAGENT
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 STRIDES PHARMA SCIENCE LIMITED.
17.29.1 COMPANY SNAPSHOT
17.29.2 REVENUE ANALYSIS
17.29.3 PRODUCT PORTFOLIO
17.29.4 RECENT DEVELOPMENT
17.3 TORRENT PHARMACEUTICALS LTD.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENTS
17.31 USV PRIVATE LIMITED.
17.31.1 COMPANY SNAPSHOT
17.31.2 SERVICE PORTFOLIO
17.31.3 RECENT DEVELOPMENT
17.32 WOCKHARDT LIMITED
17.32.1 COMPANY SNAPSHOT
17.32.2 REVENUE ANALYSIS
17.32.3 PRODUCT PORTFOLIO
17.32.4 RECENT DEVELOPMENT
17.33 MCKESSON CORPORATION
17.33.1 COMPANY SNAPSHOT
17.33.2 REVENUE ANALYSIS
17.33.3 PRODUCT PORTFOLIO
17.33.4 RECENT DEVELOPMENT
17.34 CENCORA, INC.
17.34.1 COMPANY SNAPSHOT
17.34.2 REVENUE ANALYSIS
17.34.3 PRODUCT PORTFOLIO
17.34.4 RECENT DEVELOPMENT
17.35 CARDINAL HEALTH
17.35.1 COMPANY SNAPSHOT
17.35.2 REVENUE ANALYSIS
17.35.3 PRODUCT PORTFOLIO
17.35.4 RECENT DEVELOPMENT
17.36 ALVOGEN
17.36.1 COMPANY SNAPSHOT
17.36.2 SERVICE PORTFOLIO
17.36.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 BRAND COMPARATIVE ANALYSIS OF THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
TABLE 2 PATENT LANDSCAPE
TABLE 3 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA HORMONES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA ANTI-PSYCHOTICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA PAIN MANAGEMENT AND ANTI-INFLAMMATORY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA DIABETES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 78 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 80 MIDDLE EAST AND AFRICA ORAL IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 81 MIDDLE EAST AND AFRICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 MIDDLE EAST AND AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 83 MIDDLE EAST AND AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 MIDDLE EAST AND AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 85 MIDDLE EAST AND AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 87 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 MIDDLE EAST AND AFRICA VALUE-ADDED BRANDED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 89 MIDDLE EAST AND AFRICA TRADE NAMED GENERICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 90 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 91 MIDDLE EAST AND AFRICA ADULT IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 92 MIDDLE EAST AND AFRICA GERIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 93 MIDDLE EAST AND AFRICA PEDIATRIC IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 94 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 95 MIDDLE EAST AND AFRICA HOSPITALS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 96 MIDDLE EAST AND AFRICA CLINICS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 97 MIDDLE EAST AND AFRICA HOMECARE IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 98 MIDDLE EAST AND AFRICA ACADEMIC & RESEARCH INSTITUTES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 99 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 100 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 102 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 104 MIDDLE EAST AND AFRICA DIRECT TENDERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 105 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 106 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 107 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 108 MIDDLE EAST AND AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 MIDDLE EAST AND AFRICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 MIDDLE EAST AND AFRICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 MIDDLE EAST AND AFRICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 MIDDLE EAST AND AFRICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 MIDDLE EAST AND AFRICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 MIDDLE EAST AND AFRICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 MIDDLE EAST AND AFRICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 MIDDLE EAST AND AFRICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 MIDDLE EAST AND AFRICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 MIDDLE EAST AND AFRICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 MIDDLE EAST AND AFRICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 MIDDLE EAST AND AFRICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 MIDDLE EAST AND AFRICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 MIDDLE EAST AND AFRICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 MIDDLE EAST AND AFRICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 MIDDLE EAST AND AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 MIDDLE EAST AND AFRICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 MIDDLE EAST AND AFRICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 MIDDLE EAST AND AFRICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 MIDDLE EAST AND AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 MIDDLE EAST AND AFRICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 MIDDLE EAST AND AFRICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 MIDDLE EAST AND AFRICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 MIDDLE EAST AND AFRICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 MIDDLE EAST AND AFRICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 MIDDLE EAST AND AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 MIDDLE EAST AND AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 MIDDLE EAST AND AFRICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 MIDDLE EAST AND AFRICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 MIDDLE EAST AND AFRICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 MIDDLE EAST AND AFRICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 MIDDLE EAST AND AFRICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 MIDDLE EAST AND AFRICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 MIDDLE EAST AND AFRICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 MIDDLE EAST AND AFRICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 MIDDLE EAST AND AFRICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 MIDDLE EAST AND AFRICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 MIDDLE EAST AND AFRICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 MIDDLE EAST AND AFRICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 MIDDLE EAST AND AFRICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 156 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 MIDDLE EAST AND AFRICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 MIDDLE EAST AND AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 MIDDLE EAST AND AFRICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 MIDDLE EAST AND AFRICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MIDDLE EAST AND AFRICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 MIDDLE EAST AND AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 MIDDLE EAST AND AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 MIDDLE EAST AND AFRICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 167 MIDDLE EAST AND AFRICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 MIDDLE EAST AND AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 MIDDLE EAST AND AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 172 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 173 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 SAUDI ARABIA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 176 SAUDI ARABIA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 SAUDI ARABIA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 SAUDI ARABIA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 SAUDI ARABIA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 180 SAUDI ARABIA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 SAUDI ARABIA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 SAUDI ARABIA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 SAUDI ARABIA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 SAUDI ARABIA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 SAUDI ARABIA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 SAUDI ARABIA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 SAUDI ARABIA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 SAUDI ARABIA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 SAUDI ARABIA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 SAUDI ARABIA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 SAUDI ARABIA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 SAUDI ARABIA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 SAUDI ARABIA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 SAUDI ARABIA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 SAUDI ARABIA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 SAUDI ARABIA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 SAUDI ARABIA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 SAUDI ARABIA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 SAUDI ARABIA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 SAUDI ARABIA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 SAUDI ARABIA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 SAUDI ARABIA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 SAUDI ARABIA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 SAUDI ARABIA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 SAUDI ARABIA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 SAUDI ARABIA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 SAUDI ARABIA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 SAUDI ARABIA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 SAUDI ARABIA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 SAUDI ARABIA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 SAUDI ARABIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 SAUDI ARABIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 213 SAUDI ARABIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 SAUDI ARABIA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 SAUDI ARABIA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 SAUDI ARABIA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 SAUDI ARABIA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 SAUDI ARABIA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 SAUDI ARABIA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 SAUDI ARABIA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 SAUDI ARABIA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 SAUDI ARABIA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 SAUDI ARABIA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 224 SAUDI ARABIA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 SAUDI ARABIA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 SAUDI ARABIA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 SAUDI ARABIA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 SAUDI ARABIA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 SAUDI ARABIA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 SAUDI ARABIA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 SAUDI ARABIA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 SAUDI ARABIA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 SAUDI ARABIA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 SAUDI ARABIA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 235 SAUDI ARABIA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 SAUDI ARABIA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 SAUDI ARABIA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 SAUDI ARABIA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 SAUDI ARABIA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 240 SAUDI ARABIA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 241 SAUDI ARABIA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 242 SAUDI ARABIA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 UNITED ARAB EMIRATES ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 UNITED ARAB EMIRATES DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 UNITED ARAB EMIRATES ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 UNITED ARAB EMIRATES ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 UNITED ARAB EMIRATES BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 UNITED ARAB EMIRATES CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 UNITED ARAB EMIRATES DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 UNITED ARAB EMIRATES ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 UNITED ARAB EMIRATES CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 UNITED ARAB EMIRATES HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 UNITED ARAB EMIRATES STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 UNITED ARAB EMIRATES SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 UNITED ARAB EMIRATES ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 UNITED ARAB EMIRATES PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 UNITED ARAB EMIRATES ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 UNITED ARAB EMIRATES THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 UNITED ARAB EMIRATES OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 UNITED ARAB EMIRATES ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 UNITED ARAB EMIRATES PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 UNITED ARAB EMIRATES PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 UNITED ARAB EMIRATES FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 UNITED ARAB EMIRATES LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 UNITED ARAB EMIRATES STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 UNITED ARAB EMIRATES COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 UNITED ARAB EMIRATES FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 UNITED ARAB EMIRATES BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 UNITED ARAB EMIRATES PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 271 UNITED ARAB EMIRATES ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 UNITED ARAB EMIRATES ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 UNITED ARAB EMIRATES NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 UNITED ARAB EMIRATES NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 UNITED ARAB EMIRATES ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 UNITED ARAB EMIRATES TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 UNITED ARAB EMIRATES ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 278 UNITED ARAB EMIRATES ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 UNITED ARAB EMIRATES SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 UNITED ARAB EMIRATES SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 UNITED ARAB EMIRATES TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 UNITED ARAB EMIRATES ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 UNITED ARAB EMIRATES MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 UNITED ARAB EMIRATES NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 UNITED ARAB EMIRATES ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 286 UNITED ARAB EMIRATES SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 UNITED ARAB EMIRATES FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 UNITED ARAB EMIRATES PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 UNITED ARAB EMIRATES THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 UNITED ARAB EMIRATES NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 291 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 UNITED ARAB EMIRATES CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 UNITED ARAB EMIRATES PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 UNITED ARAB EMIRATES ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 UNITED ARAB EMIRATES SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 UNITED ARAB EMIRATES HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 UNITED ARAB EMIRATES DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 UNITED ARAB EMIRATES NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 UNITED ARAB EMIRATES GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 UNITED ARAB EMIRATES DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 UNITED ARAB EMIRATES OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 UNITED ARAB EMIRATES ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 UNITED ARAB EMIRATES INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 UNITED ARAB EMIRATES TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 308 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 309 UNITED ARAB EMIRATES BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 310 UNITED ARAB EMIRATES RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 EGYPT BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 312 EGYPT ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 EGYPT DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 EGYPT ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 EGYPT ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 EGYPT BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 EGYPT CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 EGYPT DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 EGYPT ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 EGYPT CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 321 EGYPT HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 EGYPT STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 EGYPT SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 EGYPT ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 EGYPT PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 EGYPT ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 EGYPT THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 EGYPT OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 EGYPT ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 330 EGYPT PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 EGYPT PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 EGYPT FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 EGYPT LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 EGYPT STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 EGYPT COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 336 EGYPT FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 EGYPT BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 EGYPT PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 EGYPT ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 EGYPT ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 341 EGYPT NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 EGYPT NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 EGYPT ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 344 EGYPT TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 EGYPT ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 EGYPT ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 EGYPT SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 EGYPT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 349 EGYPT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 EGYPT ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 EGYPT MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 EGYPT NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 EGYPT ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 EGYPT SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 EGYPT FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 EGYPT PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 EGYPT THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 EGYPT NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 EGYPT BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 360 EGYPT CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 EGYPT PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 EGYPT ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 363 EGYPT SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 364 EGYPT HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 EGYPT DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 EGYPT NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 EGYPT GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 EGYPT DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 EGYPT OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 EGYPT BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 371 EGYPT ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 EGYPT INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 EGYPT TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 EGYPT BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 EGYPT BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 376 EGYPT BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 377 EGYPT BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 378 EGYPT RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 SOUTH AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 380 SOUTH AFRICA ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 SOUTH AFRICA DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 SOUTH AFRICA ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 SOUTH AFRICA ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 SOUTH AFRICA BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 SOUTH AFRICA CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 386 SOUTH AFRICA DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 SOUTH AFRICA ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 SOUTH AFRICA CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 SOUTH AFRICA HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 SOUTH AFRICA STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 391 SOUTH AFRICA SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 392 SOUTH AFRICA ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 SOUTH AFRICA PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 SOUTH AFRICA ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 SOUTH AFRICA THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 SOUTH AFRICA OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 SOUTH AFRICA ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 SOUTH AFRICA PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 399 SOUTH AFRICA PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 SOUTH AFRICA FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 SOUTH AFRICA LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 SOUTH AFRICA STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 SOUTH AFRICA COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 SOUTH AFRICA FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 SOUTH AFRICA BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 SOUTH AFRICA PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 SOUTH AFRICA ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 SOUTH AFRICA ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 SOUTH AFRICA NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 SOUTH AFRICA NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 SOUTH AFRICA ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 SOUTH AFRICA TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 413 SOUTH AFRICA ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 414 SOUTH AFRICA ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 SOUTH AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 SOUTH AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 SOUTH AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 SOUTH AFRICA ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 SOUTH AFRICA MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 SOUTH AFRICA NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 SOUTH AFRICA ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 SOUTH AFRICA SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 SOUTH AFRICA FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 SOUTH AFRICA PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 SOUTH AFRICA THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 SOUTH AFRICA NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 SOUTH AFRICA BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 428 SOUTH AFRICA CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 SOUTH AFRICA PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 SOUTH AFRICA ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 SOUTH AFRICA SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 SOUTH AFRICA HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 433 SOUTH AFRICA DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 434 SOUTH AFRICA NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 SOUTH AFRICA GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 SOUTH AFRICA DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 SOUTH AFRICA OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 SOUTH AFRICA BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 439 SOUTH AFRICA ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 SOUTH AFRICA INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 441 SOUTH AFRICA TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 442 SOUTH AFRICA BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 SOUTH AFRICA BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 444 SOUTH AFRICA BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 445 SOUTH AFRICA BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 446 SOUTH AFRICA RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 447 ISRAEL BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 448 ISRAEL ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 ISRAEL DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 ISRAEL ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 ISRAEL ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 ISRAEL BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 ISRAEL CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 ISRAEL DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 ISRAEL ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 ISRAEL CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 ISRAEL HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 ISRAEL STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 ISRAEL SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 ISRAEL ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 ISRAEL PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 ISRAEL ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 ISRAEL THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 ISRAEL OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 ISRAEL ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 ISRAEL PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 ISRAEL PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 ISRAEL FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 ISRAEL LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 ISRAEL STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 471 ISRAEL COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 ISRAEL FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 ISRAEL BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 ISRAEL PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 ISRAEL ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 ISRAEL ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 ISRAEL NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 ISRAEL NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 ISRAEL ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 ISRAEL TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 ISRAEL ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 ISRAEL ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 ISRAEL SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 ISRAEL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 ISRAEL TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 486 ISRAEL ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 ISRAEL MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 ISRAEL NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 ISRAEL ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 ISRAEL SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 491 ISRAEL FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 492 ISRAEL PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 ISRAEL THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 ISRAEL NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 ISRAEL BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 496 ISRAEL CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 ISRAEL PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 498 ISRAEL ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 499 ISRAEL SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 ISRAEL HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 ISRAEL DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 ISRAEL NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 ISRAEL GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 ISRAEL DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 ISRAEL OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 ISRAEL BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 507 ISRAEL ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 ISRAEL INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 ISRAEL TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 ISRAEL BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 ISRAEL BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 512 ISRAEL BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 513 ISRAEL BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 514 ISRAEL RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 KUWAIT BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 516 KUWAIT ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 KUWAIT DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 KUWAIT ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 KUWAIT ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 KUWAIT BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 KUWAIT CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 KUWAIT DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 KUWAIT ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 KUWAIT CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 KUWAIT HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 KUWAIT STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 KUWAIT SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 528 KUWAIT ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 KUWAIT PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 KUWAIT ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 KUWAIT THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 KUWAIT OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 533 KUWAIT ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 534 KUWAIT PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 KUWAIT PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 536 KUWAIT FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 KUWAIT LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 KUWAIT STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 539 KUWAIT COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 KUWAIT FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 541 KUWAIT BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 542 KUWAIT PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 KUWAIT ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 KUWAIT ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 545 KUWAIT NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 KUWAIT NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 547 KUWAIT ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 548 KUWAIT TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 KUWAIT ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 KUWAIT ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 KUWAIT SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 KUWAIT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 KUWAIT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 KUWAIT ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 KUWAIT MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 KUWAIT NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 KUWAIT ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 KUWAIT SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 KUWAIT FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 KUWAIT PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 KUWAIT THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 562 KUWAIT NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 563 KUWAIT BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 564 KUWAIT CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 KUWAIT PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 KUWAIT ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 KUWAIT SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 KUWAIT HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 KUWAIT DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 KUWAIT NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 KUWAIT GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 KUWAIT DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 KUWAIT OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 KUWAIT BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 575 KUWAIT ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 KUWAIT INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 KUWAIT TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 KUWAIT BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 KUWAIT BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 580 KUWAIT BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 581 KUWAIT BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 582 KUWAIT RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 BAHRAIN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 584 BAHRAIN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 585 BAHRAIN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 586 BAHRAIN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 BAHRAIN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 588 BAHRAIN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 589 BAHRAIN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 BAHRAIN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 591 BAHRAIN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 592 BAHRAIN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 BAHRAIN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 BAHRAIN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 BAHRAIN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 BAHRAIN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 BAHRAIN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 BAHRAIN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 599 BAHRAIN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 BAHRAIN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 BAHRAIN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 BAHRAIN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 BAHRAIN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 BAHRAIN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 BAHRAIN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 BAHRAIN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 BAHRAIN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 BAHRAIN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 BAHRAIN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 BAHRAIN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 BAHRAIN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 BAHRAIN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 613 BAHRAIN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 614 BAHRAIN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 BAHRAIN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 BAHRAIN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 BAHRAIN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 BAHRAIN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 BAHRAIN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 BAHRAIN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 BAHRAIN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 BAHRAIN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 BAHRAIN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 624 BAHRAIN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 BAHRAIN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 BAHRAIN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 627 BAHRAIN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 628 BAHRAIN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 BAHRAIN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 BAHRAIN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 BAHRAIN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 632 BAHRAIN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 633 BAHRAIN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 634 BAHRAIN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 BAHRAIN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 BAHRAIN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 BAHRAIN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 BAHRAIN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 BAHRAIN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 BAHRAIN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 641 BAHRAIN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 642 BAHRAIN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 643 BAHRAIN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 BAHRAIN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 BAHRAIN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 BAHRAIN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 647 BAHRAIN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 648 BAHRAIN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 649 BAHRAIN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 650 BAHRAIN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 651 QATAR BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 652 QATAR ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 653 QATAR DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 654 QATAR ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 655 QATAR ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 QATAR BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 QATAR CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 QATAR DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 QATAR ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 QATAR CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 QATAR HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 QATAR STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 663 QATAR SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 664 QATAR ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 QATAR PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 QATAR ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 QATAR THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 668 QATAR OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 QATAR ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 QATAR PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 671 QATAR PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 672 QATAR FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 673 QATAR LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 674 QATAR STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 QATAR COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 QATAR FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 677 QATAR BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 678 QATAR PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 QATAR ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 680 QATAR ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 681 QATAR NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 QATAR NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 683 QATAR ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 684 QATAR TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 QATAR ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 686 QATAR ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 QATAR SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 688 QATAR SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 689 QATAR TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 690 QATAR ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 691 QATAR MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 692 QATAR NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 QATAR ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 694 QATAR SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 695 QATAR FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 QATAR PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 697 QATAR THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 698 QATAR NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 699 QATAR BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 700 QATAR CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 QATAR PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 QATAR ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 703 QATAR SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 QATAR HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 QATAR DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 QATAR NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 QATAR GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 QATAR DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 QATAR OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 QATAR BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 711 QATAR ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 QATAR INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 713 QATAR TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 714 QATAR BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 715 QATAR BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 716 QATAR BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 717 QATAR BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 718 QATAR RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 OMAN BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
TABLE 720 OMAN ANTI-HYPERTENSIVE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 721 OMAN DIURETICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 OMAN ACE INHIBITORS (ANGIOTENSIN-CONVERTING ENZYME INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 OMAN ANGIOTENSIN II RECEPTOR BLOCKERS (ARBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 724 OMAN BETA BLOCKERS (BBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 OMAN CALCIUM CHANNEL BLOCKERS (CCBS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 OMAN DIRECT VASODILATORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 OMAN ALPHA-1 BLOCKERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 728 OMAN CENTRAL ALPHA-2 AGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 OMAN HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 730 OMAN STEROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 731 OMAN SEX HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 OMAN ESTROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 733 OMAN PROGESTOGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 734 OMAN ANDROGENS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 735 OMAN THYROID HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 736 OMAN OTHER HORMONES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 OMAN ANTIMETABOLITES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 738 OMAN PURINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 739 OMAN PYRIMIDINE ANALOGUES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 OMAN FOLATE ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 741 OMAN LIPID LOWERING DRUGS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 742 OMAN STATINS (HMG-COA REDUCTASE INHIBITORS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 743 OMAN COMBINATION PRODUCTS AND OTHER AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 744 OMAN FIBRATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 745 OMAN BILE ACID SEQUESTRANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 OMAN PCSK9 INHIBITORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 747 OMAN ANTI-EPILEPTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 748 OMAN ALKYLATING AGENTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 749 OMAN NITROGEN MUSTARDS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 OMAN NITROSOUREAS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 OMAN ALKYL SULFONATES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 OMAN TRIAZENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 753 OMAN ETHYLENIMINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 OMAN ANTI-DEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 OMAN SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 OMAN SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 OMAN TRICYCLIC ANTIDEPRESSANTS (TCAS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 758 OMAN ATYPICAL ANTIDEPRESSANTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 OMAN MONOAMINE OXIDASE INHIBITORS (MAOIS) IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 OMAN NMDA RECEPTOR ANTAGONISTS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 OMAN ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 OMAN SECOND-GENERATION (ATYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 763 OMAN FIRST-GENERATION (TYPICAL) ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 764 OMAN PHENOTHIAZINES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 765 OMAN THIOXANTHENES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 OMAN NEXT-GENERATION ANTIPSYCHOTICS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 OMAN BRANDED GENERICS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 768 OMAN CARDIOVASCULAR DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 OMAN PAIN MANAGEMENT AND ANTI‑INFLAMMATORY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 OMAN ONCOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 771 OMAN SOLID TUMORS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 OMAN HEMATOLOGIC MALIGNANCIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 OMAN DIABETES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 774 OMAN NEUROLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 OMAN GASTROINTESTINAL DISEASES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 776 OMAN DERMATOLOGY IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 777 OMAN OTHERS IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 778 OMAN BRANDED GENERICS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 779 OMAN ORAL IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 780 OMAN INJECTABLE IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 781 OMAN TOPICAL ADMINISTRATION IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 782 OMAN BRANDED GENERICS MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 783 OMAN BRANDED GENERICS MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 784 OMAN BRANDED GENERICS MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 785 OMAN BRANDED GENERICS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 786 OMAN RETAIL PHARMACIES IN BRANDED GENERICS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 787 REST OF MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EXECUTIVE SUMMARY
FIGURE 10 STRATEGIC DECISIONS
FIGURE 11 NINE SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET, BY DRUG CLASS (2024)
FIGURE 12 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: SEGMENTATION
FIGURE 13 PATENT EXPIRATIONS OF BLOCKBUSTER DRUGS ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 ANTI-HYPERTENSIVE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET IN 2025 & 2032
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET
FIGURE 16 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, 2024
FIGURE 17 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, 2025 TO 2032 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, CAGR (2025- 2032)
FIGURE 19 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, 2024
FIGURE 21 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, CAGR (2025- 2032)
FIGURE 23 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 25 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, 2025 TO 2032 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025- 2032)
FIGURE 27 MIDDLE EAST AND AFRICA BRANDED GENERIC MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2024
FIGURE 29 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, 2025 TO 2032 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, CAGR (2025- 2032)
FIGURE 31 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2024
FIGURE 33 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, 2025 TO 2032 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2025- 2032)
FIGURE 35 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, 2024
FIGURE 37 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)
FIGURE 38 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, CAGR (2025- 2032)
FIGURE 39 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 41 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, 2025 TO 2032 (USD THOUSAND)
FIGURE 42 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025- 2032)
FIGURE 43 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: SNAPSHOT (2024)
FIGURE 45 MIDDLE EAST AND AFRICA BRANDED GENERICS MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
